DIPG
MCID: DFF037
MIFTS: 43

Diffuse Intrinsic Pontine Glioma (DIPG)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Diffuse Intrinsic Pontine Glioma

MalaCards integrated aliases for Diffuse Intrinsic Pontine Glioma:

Name: Diffuse Intrinsic Pontine Glioma 53 59 6 17 72
Dipg 53 59
Infiltrative Brainstem Glioma 53

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA497188
UMLS 72 C2986658

Summaries for Diffuse Intrinsic Pontine Glioma

MalaCards based summary : Diffuse Intrinsic Pontine Glioma, also known as dipg, is related to glioma and glial tumor. An important gene associated with Diffuse Intrinsic Pontine Glioma is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are TCR Signaling (Qiagen) and DNA Damage. The drugs Lomustine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, pons and eye, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 75 A diffuse intrinsic pontine glioma (DIPG) is a tumour located in the pons (middle) of the brain stem.... more...

Related Diseases for Diffuse Intrinsic Pontine Glioma

Diseases related to Diffuse Intrinsic Pontine Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 glioma 11.3
2 glial tumor 11.3
3 glioblastoma multiforme 10.7
4 glioblastoma 10.7
5 brain cancer 10.6
6 astrocytoma 10.6
7 hydrocephalus 10.4
8 neutropenia 10.4
9 cranial nerve palsy 10.4
10 congenital hydrocephalus 10.4
11 ataxia and polyneuropathy, adult-onset 10.3
12 grade iii astrocytoma 10.3
13 brain tumor, childhood 10.3
14 pilocytic astrocytoma 10.3
15 retinoblastoma 10.3
16 respiratory failure 10.3
17 facial paralysis 10.3
18 familial retinoblastoma 10.3
19 lymphopenia 10.3
20 juvenile pilocytic astrocytoma 10.3
21 alopecia 10.3
22 rare surgical neurologic disease 10.3
23 fibrodysplasia ossificans progressiva 10.1
24 glioma susceptibility 1 10.1
25 medulloblastoma 10.1
26 neurofibromatosis, type iv, of riccardi 10.1
27 hydrocephalus, congenital, 1 10.1
28 neuroblastoma 1 10.1
29 wilms tumor 5 10.1
30 immunodeficiency, common variable, 10 10.1
31 exanthem 10.1
32 neonatal respiratory failure 10.1
33 obstructive hydrocephalus 10.1
34 communicating hydrocephalus 10.1
35 thrombocytopenia 10.1
36 malignant glioma 10.1
37 vaccinia 10.1
38 craniopharyngioma 10.1
39 brain stem glioma 10.1
40 hypokalemia 10.1
41 fibrillary astrocytoma 10.1
42 intracranial hypertension 10.1
43 47,xyy 10.1
44 subependymoma 10.1
45 high-grade astrocytoma 10.1
46 benign idiopathic neonatal seizures 10.1
47 rare tumor 10.1
48 polyploidy 10.1
49 gliomatosis cerebri 10.0
50 fanconi anemia, complementation group n 9.9 BRIP1 BRCA2

Graphical network of the top 20 diseases related to Diffuse Intrinsic Pontine Glioma:



Diseases related to Diffuse Intrinsic Pontine Glioma

Symptoms & Phenotypes for Diffuse Intrinsic Pontine Glioma

GenomeRNAi Phenotypes related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 10.02 ACVR1
2 Decreased substrate adherent cell growth GR00193-A-3 10.02 ACVR1 CHEK2
3 Decreased substrate adherent cell growth GR00193-A-4 10.02 ACVR1 CHEK2
4 Decreased viability GR00221-A-1 10 NF1
5 Decreased viability GR00221-A-2 10 CHEK2 NF1
6 Decreased viability GR00221-A-3 10 CHEK2
7 Decreased viability GR00221-A-4 10 ACVR1 CHEK2 NF1
8 Decreased viability GR00342-S-2 10 CHEK2
9 Decreased viability GR00402-S-2 10 ACVR1 CHEK2 NF1
10 Decreased ionizing radiation sensitivity GR00232-A-1 9.67 ACVR1 BRCA2 BRIP1 NF1
11 Decreased viability with cisplatin GR00101-A-4 9.16 BRCA2 BRIP1
12 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.13 BRCA2 BRIP1 CHEK2
13 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA2 BRIP1

MGI Mouse Phenotypes related to Diffuse Intrinsic Pontine Glioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.72 ACVR1 BRCA2 BRIP1 CHEK2 NF1
2 endocrine/exocrine gland MP:0005379 9.56 BRCA2 BRIP1 CHEK2 NF1
3 homeostasis/metabolism MP:0005376 9.55 ACVR1 BRCA2 BRIP1 CHEK2 NF1
4 neoplasm MP:0002006 9.35 ACVR1 BRCA2 BRIP1 CHEK2 NF1
5 nervous system MP:0003631 9.02 ACVR1 BRCA2 BRIP1 CHEK2 NF1

Drugs & Therapeutics for Diffuse Intrinsic Pontine Glioma

Drugs for Diffuse Intrinsic Pontine Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
8
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
9
leucovorin Approved Phase 3 58-05-9 143 6006
10
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
11
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
12
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
13
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
15
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
16
Nimotuzumab Investigational Phase 2, Phase 3 780758-10-3, 828933-61-3
17 Topoisomerase Inhibitors Phase 3
18 Antimetabolites Phase 3
19 Antimetabolites, Antineoplastic Phase 3
20 Antineoplastic Agents, Phytogenic Phase 3
21 Etoposide phosphate Phase 3
22 Tubulin Modulators Phase 3
23 Antimitotic Agents Phase 3
24 Folate Phase 3
25 Vitamin B9 Phase 3
26 Vitamin B Complex Phase 3
27 Dermatologic Agents Phase 3
28 Hormone Antagonists Phase 3
29 Folic Acid Antagonists Phase 3
30 glucocorticoids Phase 3
31 Hormones Phase 3
32 Antineoplastic Agents, Hormonal Phase 3
33 Nucleic Acid Synthesis Inhibitors Phase 3
34
Isophosphamide mustard Phase 3 0
35 Calcium, Dietary Phase 3
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
37 Antibodies Phase 2, Phase 3
38 Antineoplastic Agents, Immunological Phase 2, Phase 3
39 Antibodies, Monoclonal Phase 2, Phase 3
40 Immunoglobulins Phase 2, Phase 3
41 Neurotransmitter Agents Phase 3
42 Tranquilizing Agents Phase 3
43 GABA Agents Phase 3
44 Antimanic Agents Phase 3
45 Central Nervous System Depressants Phase 3
46 Psychotropic Drugs Phase 3
47 Anticonvulsants Phase 3
48 Antirheumatic Agents Phase 3
49 Antiparasitic Agents Phase 3
50 Anthelmintics Phase 3

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
2 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
3 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
4 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
5 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
6 A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02887040 Phase 3 Atengenal;Astugenal
7 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
8 Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma Completed NCT00600054 Phase 2
9 Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children Completed NCT01777633 Phase 1, Phase 2
10 A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System Completed NCT01751308 Phase 1, Phase 2 Cabazitaxel (XRP6258)
11 Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Completed NCT01182350 Phase 2 Bevacizumab;Erlotinib;Temozolomide
12 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas Completed NCT02343406 Phase 2 Lomustine;ABT-414;Temozolomide
13 A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) in Children With Diffuse Pontine Gliomas Completed NCT00036569 Phase 2
14 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
15 An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy Recruiting NCT03566199 Phase 1, Phase 2 Panobinostat Nanoparticle Formulation MTX110;Convection-Enhanced Delivery (CED)
16 An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) Recruiting NCT02758366 Phase 2 Doxorubicin
17 A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations Recruiting NCT03352427 Phase 2 Dasatinib;Everolimus
18 A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma Recruiting NCT03690869 Phase 1, Phase 2 REGN2810 (monotherapy);REGN2810 (maintenance)
19 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT02233049 Phase 2 Erlotinib;Everolimus;Dasatinib
20 Phase 2 Randomized Study of RT and Reirradiation at Relapse vs Multiple Elective RT Courses With Same Concomitant CT for Newly Diagnosed Recruiting NCT03620032 Phase 2 Nimotuzumab;Vinorelbine
21 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
22 A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas Active, not recruiting NCT02750891 Phase 1, Phase 2 DSP-7888
23 A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG) Active, not recruiting NCT02742883 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
24 A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
25 Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma Active, not recruiting NCT01469247 Phase 1, Phase 2
26 A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Active, not recruiting NCT02607124 Phase 1, Phase 2 Ribociclib
27 A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS Active, not recruiting NCT03257631 Phase 2 Pomalidomide
28 Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Not yet recruiting NCT04049669 Phase 2 Indoximod;Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
29 A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma Terminated NCT01836549 Phase 2 imetelstat sodium
30 Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group - Terminated NCT01517776 Phase 2 Cilengitide;Temozolomide
31 A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma. Terminated NCT01774253 Phase 2 Vismodegib
32 A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation Withdrawn NCT03632317 Phase 2 Panobinostat;Everolimus
33 Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma Completed NCT00996723 Phase 1 vandetanib and dasatinib
34 Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). Completed NCT01688401 Phase 1 Melphalan hydrochloride
35 Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma Completed NCT01393912 Phase 1 Crenolanib
36 Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Completed NCT01644773 Phase 1 Crizotinib;Dasatinib
37 A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas Completed NCT01222754 Phase 1 Lenalidomide
38 Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study Completed NCT01165333 Phase 1 Cilengitide dose escalation;Cilengitide
39 A Phase I Study of Motexafin Gadolinium (Xcytrin, NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood Completed NCT00003909 Phase 1 motexafin gadolinium
40 A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging With Gadolinium in Children With Diffuse Intrinsic Pontine Glioma Recruiting NCT03086616 Phase 1 Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
41 ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas Recruiting NCT03416530 Phase 1 ONC201
42 A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) With Temsirolimus in Children With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG) Recruiting NCT02420613 Phase 1 Temsirolimus;Vorinostat
43 Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors Recruiting NCT02644460 Phase 1 Abemaciclib
44 Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy Recruiting NCT03696355 Phase 1 GDC-0084
45 Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma Recruiting NCT02717455 Phase 1 LBH589
46 Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Recruiting NCT03178032 Phase 1
47 A Phase I Study of Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy Recruiting NCT01502917 Phase 1
48 Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma Recruiting NCT03389802 Phase 1
49 A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors Recruiting NCT03967093 Phase 1 BXQ-350
50 A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Recruiting NCT03605550 Phase 1 PTC596

Search NIH Clinical Center for Diffuse Intrinsic Pontine Glioma

Genetic Tests for Diffuse Intrinsic Pontine Glioma

Anatomical Context for Diffuse Intrinsic Pontine Glioma

MalaCards organs/tissues related to Diffuse Intrinsic Pontine Glioma:

41
Brain, Pons, Eye, Spinal Cord, Testes, T Cells, Lung

Publications for Diffuse Intrinsic Pontine Glioma

Articles related to Diffuse Intrinsic Pontine Glioma:

(show top 50) (show all 449)
# Title Authors PMID Year
1
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. 38
30861105 2019
2
Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. 38
31201162 2019
3
Robot-assisted stereotactic brainstem biopsy in children: prospective cohort study. 38
30523502 2019
4
Developmental origins and oncogenic pathways in malignant brain tumors. 38
30945456 2019
5
Authors' Reply to "Translating palbociclib to the clinic for DIPG - What is truly achievable?" 38
31231019 2019
6
Translating palbociclib to the clinic for DIPG - What is truly achievable? 38
31235425 2019
7
Abnormal Neural Activity in Children With Diffuse Intrinsic Pontine Glioma Had Manifested Deficit in Behavioral Inhibition: A Resting-State Functional MRI Study. 38
31162235 2019
8
Comment on: Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study. 38
30767367 2019
9
Signal Transduction in Diffuse Intrinsic Pontine Glioma. 38
31328874 2019
10
Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. 38
31360809 2019
11
Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials. 38
31290035 2019
12
High Prevalence of Developmental Venous Anomaly in Diffuse Intrinsic Pontine Gliomas: A Pediatric Control Study. 38
31342064 2019
13
A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. 38
31324890 2019
14
Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. 38
31315671 2019
15
Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells. 38
31238504 2019
16
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. 38
31227500 2019
17
Unlocking the translational potential of circulating nucleosomes for liquid biopsy in diffuse intrinsic pontine glioma. 38
31157545 2019
18
CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis? 38
31097409 2019
19
The 100 most-cited articles about diffuse intrinsic pontine glioma: a bibliometric analysis. 38
31203394 2019
20
Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. 38
31022591 2019
21
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma. 38
30852603 2019
22
Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. 38
30976974 2019
23
ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma. 38
31225627 2019
24
A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma. 38
30610915 2019
25
Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. 38
30706132 2019
26
Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis. 38
30879125 2019
27
Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. 38
31060906 2019
28
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. 38
31086175 2019
29
Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. 38
30830679 2019
30
Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy. 38
30852713 2019
31
Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma. 38
30990879 2019
32
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. 38
31138805 2019
33
Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery. 38
30838861 2019
34
Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease. 38
31092287 2019
35
Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium. 38
30810873 2019
36
Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. 38
31036068 2019
37
Diffuse Intrinsic Pontine Gliomas Exhibit Cell Biological and Molecular Signatures of Fetal Hindbrain-Derived Neural Progenitor Cells. 38
30607770 2019
38
Target identification reveals lanosterol synthase as a vulnerability in glioma. 38
30923116 2019
39
DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for DIPGs. 38
30943283 2019
40
High frequency of H3 K27M mutations in adult midline gliomas. 38
30610375 2019
41
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. 38
30952114 2019
42
H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. 38
30770999 2019
43
Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. 38
30072503 2019
44
ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. 38
30833574 2019
45
Evidence-Based Practice: Temozolomide Beyond Glioblastoma. 38
30835007 2019
46
Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study. 38
30484948 2019
47
Re-irradiation for Paediatric Tumours. 38
30385005 2019
48
Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. 38
30978130 2019
49
Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. 38
30460397 2019
50
Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. 38
30367915 2019

Variations for Diffuse Intrinsic Pontine Glioma

ClinVar genetic disease variations for Diffuse Intrinsic Pontine Glioma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 BRCA2 NM_000059.3(BRCA2): c.4474_4477AAAG[1] (p.Glu1493fs) short repeat Pathogenic rs80359454 13:32912970-32912973 13:32338833-32338836
2 BRIP1 NM_032043.2(BRIP1): c.1045G> C (p.Ala349Pro) single nucleotide variant Likely pathogenic rs149364097 17:59878709-59878709 17:61801348-61801348
3 CHEK2 NM_007194.4(CHEK2): c.1100del (p.Thr367fs) deletion Conflicting interpretations of pathogenicity rs555607708 22:29091857-29091857 22:28695869-28695869
4 NF1 NM_000267.3(NF1): c.1888G> A (p.Val630Ile) single nucleotide variant Uncertain significance rs751795238 17:29552155-29552155 17:31225137-31225137

Expression for Diffuse Intrinsic Pontine Glioma

Search GEO for disease gene expression data for Diffuse Intrinsic Pontine Glioma.

Pathways for Diffuse Intrinsic Pontine Glioma

Pathways related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 CHEK2 BRIP1 BRCA2
2 11.8 CHEK2 BRIP1 BRCA2
3 11.34 BRIP1 BRCA2
4
Show member pathways
11.24 CHEK2 BRCA2
5 10.99 NF1 CHEK2 BRCA2
6 10.82 CHEK2 BRCA2
7 10.73 CHEK2 BRIP1 BRCA2

GO Terms for Diffuse Intrinsic Pontine Glioma

Biological processes related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.65 CHEK2 BRCA2 ACVR1
2 cellular response to DNA damage stimulus GO:0006974 9.63 CHEK2 BRIP1 BRCA2
3 DNA repair GO:0006281 9.54 CHEK2 BRIP1 BRCA2
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 CHEK2 BRCA2
5 nucleotide-excision repair GO:0006289 9.4 BRIP1 BRCA2
6 DNA damage checkpoint GO:0000077 9.32 CHEK2 BRIP1
7 response to gamma radiation GO:0010332 9.26 CHEK2 BRCA2
8 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.16 CHEK2 BRCA2
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.96 CHEK2 BRCA2
10 double-strand break repair GO:0006302 8.8 CHEK2 BRIP1 BRCA2

Molecular functions related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 8.8 CHEK2 BRIP1 ACVR1

Sources for Diffuse Intrinsic Pontine Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....